| Jun 26 |
Annexon spikes after updating late-stage results for lead asset against GBS
|
| Jun 25 |
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
|
| Jun 18 |
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
|
| Jun 17 |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
|
| Jun 6 |
Annexon Announces Pricing of $125 Million Underwritten Public Offering
|
| Jun 5 |
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
|
| Jun 5 |
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
|
| Jun 5 |
Annexon’s ANX005 offers improvement in Phase III GBS trial
|
| Jun 4 |
Annexon announces proposed public offering of common stock
|
| Jun 4 |
Annexon Announces Proposed Public Offering of Common Stock
|
